Alpine Immune Sciences Inc (NASDAQ:ALPN) was the recipient of a significant decrease in short interest during the month of November. As of November 29th, there was short interest totalling 12,700 shares, a decrease of 27.4% from the November 14th total of 17,500 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily volume of 24,400 shares, the days-to-cover ratio is presently 0.5 days.
Several equities research analysts have commented on ALPN shares. Piper Jaffray Companies dropped their price target on Alpine Immune Sciences to $8.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. They noted that the move was a valuation call. Zacks Investment Research upgraded Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Friday, December 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $9.31.
Shares of NASDAQ ALPN traded up $0.07 on Thursday, hitting $3.68. The company had a trading volume of 1,310 shares, compared to its average volume of 20,267. Alpine Immune Sciences has a 12-month low of $2.25 and a 12-month high of $8.24. The business has a 50 day moving average of $2.95 and a two-hundred day moving average of $3.88. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $60.41 million, a P/E ratio of -1.44 and a beta of 1.78.
Institutional investors and hedge funds have recently modified their holdings of the stock. Hikari Power Ltd raised its stake in Alpine Immune Sciences by 52.9% during the third quarter. Hikari Power Ltd now owns 185,587 shares of the biotechnology company’s stock valued at $735,000 after buying an additional 64,224 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Alpine Immune Sciences by 67.7% during the 2nd quarter. Vanguard Group Inc. now owns 202,582 shares of the biotechnology company’s stock worth $853,000 after purchasing an additional 81,800 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Alpine Immune Sciences during the 2nd quarter worth approximately $90,000. Finally, Renaissance Technologies LLC raised its position in shares of Alpine Immune Sciences by 10.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,261 shares of the biotechnology company’s stock worth $447,000 after purchasing an additional 10,400 shares during the period. 46.80% of the stock is owned by hedge funds and other institutional investors.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
See Also: Blue-Chip Stocks
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.